 |
0 Diseases |  |
1 Trial |
|
1 Trial |  |
2 News |  |
- | PCUR-101 / Pellficure
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of PCUR-101 in Combination With ADT in Patients With mCRPC (clinicaltrials.gov) - Sep 29, 2022
P1, N=48, Recruiting, Sponsor: Pellficure Pharmaceuticals, Inc
Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023
- || PCUR-101 / Pellficure
Enrollment open, Trial initiation date, Combination therapy, Metastases: Study of PCUR-101 in Combination With ADT in Patients With mCRPC (clinicaltrials.gov) - Mar 3, 2021
P1, N=48, Recruiting, Sponsor: Pellficure Pharmaceuticals, Inc
Trial completion date: Jun 2023 --> Dec 2023 | Trial primary completion date: Jun 2023 --> Dec 2023 Not yet recruiting --> Recruiting | Initiation date: Jan 2021 --> Apr 2021
- || PCUR-101 / Pellficure
New P1 trial, Combination therapy, Metastases: Study of PCUR-101 in Combination With ADT in Patients With mCRPC (clinicaltrials.gov) - Dec 20, 2020
P1, N=48, Not yet recruiting, Sponsor: Pellficure Pharmaceuticals, Inc
- ||| PCUR-101 / Pellficure
Trial termination, Combination therapy, Metastases: A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Mar 9, 2020
P1, N=12, Terminated, Sponsor: Pellficure Pharmaceuticals, Inc
Not yet recruiting --> Recruiting | Initiation date: Jan 2021 --> Apr 2021 Active, not recruiting --> Terminated; Reformulation of study drug to help reduce the pill burden as higher doses are evaluated.
- | PCUR-101 / Pellficure
Enrollment closed, Enrollment change, Combination therapy, Metastases: A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 28, 2019
P1, N=12, Active, not recruiting, Sponsor: Pellficure Pharmaceuticals, Inc
Active, not recruiting --> Terminated; Reformulation of study drug to help reduce the pill burden as higher doses are evaluated. Recruiting --> Active, not recruiting | N=48 --> 12
- | PCUR-101 / Pellficure
Enrollment open, Combination therapy, Metastases: A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Jul 31, 2017
P1, N=48, Recruiting, Sponsor: Pellficure Pharmaceuticals, Inc
Recruiting --> Active, not recruiting | N=48 --> 12 Not yet recruiting --> Recruiting
- | PCUR-101 / Pellficure
New P1 trial, Combination therapy, Metastases: A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - May 3, 2017
P1, N=48, Not yet recruiting, Sponsor: Pellficure Pharmaceuticals, Inc